Supernus Pharmaceuticals (SUPN) Institutional Ownership

Of the 288 institutional investors that purchased Supernus Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($2.06M), Pacer Advisors Inc. ($1.75M), Woodline Partners LP ($726.09K), Rubric Capital Management LP ($695.04K), Bank of America Corp DE ($553.29K), Assenagon Asset Management S.A. ($530.62K), and American Century Companies Inc. ($490.51K).

Institutional investors have bought a total of 9,633,228 shares in the last 24 months. This purchase volume represents approximately $431.93M in transactions.

Of the 139 institutional investors that sold Supernus Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Armistice Capital LLC ($2.43M), Dimensional Fund Advisors LP ($714.18K), American Century Companies Inc. ($625.94K), Aristotle Capital Boston LLC ($573.89K), UBS Group AG ($497.08K), JPMorgan Chase & Co. ($481.89K), and Stephens Investment Management Group LLC ($448.27K).

Institutional investors have sold a total of 10,079,722 shares in the last 24 months. This volume of shares sold represents approximately $457.26M in transactions.